Skip to main content

2023

01

ABN401 clinical trials phase 2- first patient enrolled

2022

05

Contract signed with MediRama for ABN401 Global Clinical Trials Phase 2

04

Capital contribution to ABTS (ABION Biotechnology and Science), ABION’s US subsidiary

2021

09

Listed on KOSDAQ

03

Joined by a strategic investor “Labgenomics” for the development of anti-cancer drug

01

ABN401 IND approved for global clinical development stage I/2 by U.S. FDA

2020

06

Research service contract signed with ADD for Pre-clinical Safety Assessment of dual gene-inserted vaccine

04

Reseach service contract signed with ADD for the production of non-clinical study drug substance of gene vaccine and siRNA

04

ABN401 Selected for Cutting-edge medical technology development project by the Korean Ministry of Health and Welfare

2019

11

Awarded for best IP R&D company by theKorean Ministry of Trade, Industry and Energy

09

ABION Signs Contract manufacturing agreement of ABN101 with Samsung Biologics

07

License-out of anti-c-MET agonist antibody technology

07

ABION Australia Pty Ltd founded as a Subsidiary

07

ABN401 IND approved for global clinical development stage I/2

2018

12

Research service contract with ADD for Target gene expression improvement and delivery efficacy research

11

License-in of SEB vaccine development technology

11

License-out of human interferon-beta variant conjugated immunocytokine (Her2)

04

ABN701 Selected for infectious disease biorisk technology development project by the Korean Ministry of Health and Welfare (Vaccine Development)

04

ABN401 Selected for a cutting-edge medical technology development project by the Korean Ministry of Health and Welfare

2017

12

License-out of composition for treatment of HPV related cancers

06

ABN401 Selected for Innovative Technology Development Project of MSS(Ministry of SMEs and Startups)

03

ABN101 Selected for Successful production of its variant for quality analysis and pre-safety profile, Leading to Next Generation of Interferon-β Agent at Osong Medical Innovation Complex

02

ABN201 Selected for Commercialization Plan Using Analysis Technology in Immune Disease of MSIT(Ministry of science, ICT and Future Planning)

2016

08

ABN401 Selected for a Korea Drug Development Fund research project

2014

07

Listed on KONEX

2009

03

ABION Research and Development Center Established

2007

04

ABION founded